Jump to content

Study: Preoperative Treatment for Early-Stage NSCLC


Recommended Posts

http://www.medicalnewstoday.com/articles/109424.php

Excerpt on NSCLC from complete article on various new findings regarding cancer:

. . . . . . . . .

Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study. [Abstract number: 7557; Poster number 34G]

Sunday, June 1

Authors: N. Altorki, M. Guarino, P. Lee, H. I. Pass, E. Filip, T. Bauer, D. Roychowdhury, T. Zaks, L. Ottesen, D. Yankelevitz

Dr. Nasser Altorki presented final data from a Phase II clinical trial showing that a drug that stops blood vessel growth (angiogenesis) to tumors is safe and highly effective for the treatment of early-stage non-small cell lung cancer. Pazopanib works by blocking the action of vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which both work by growing bloods vessels that supply nutrition to tumors. Prior to surgery to remove their tumors, 87 percent of the 26 subjects tested had a significant reduction in tumor growth.

. . . . . . . . .

(Medical News Today, Cancer/Oncology, Lung Cancer, June 2, 2008)

Disclaimer:

The information contained in these articles may or may not be in agreement with my own opinions. They are not posted as medical advice of any kind

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...